Rahul Rekhi

Co-Lead of Healthcare IT



Rahul Rekhi is head of Lazard’s Special Opportunities team and co-leads Lazard’s coverage of healthcare IT in conjunction with the Global Technology Group. He advises clients on a range of M&A and strategic advisory assignments with a particular focus on healthcare services, digital health, and consumer health. Since joining Lazard, Rahul has advised on a range of complex financial and strategic assignments, including Aetna on its merger with CVS, Express Scripts on its sale to Cigna, the Argentine government on its sovereign debt restructuring, and the Canadian government on its post-COVID financing and airline support program, among others.

Rahul was previously an economist at the President’s Council of Economic Advisers in the Obama White House, an adviser to England’s Chief Medical Officer, and a consultant for the World Bank. He was previously named a Truman Scholar, a World Economic Forum Global Shaper, a member of the Forbes “30 under 30,” and one of Business Insider’s “top bankers in digital health,” and his writings have appeared in a range of publications, including NEJM Catalyst, Health Affairs, The International Economy, and The Guardian.

Rahul is a board member of the Schuyler Center for Analysis and Advocacy, a Council on Foreign Relations Corporate Leader, an Economic Club of New York Fellow, and an Atlantik-Brücke Young Leader, and he served as an outside policy adviser for the Biden-Harris presidential campaign. Outside Lazard, he directs the Next Bretton Woods Group at the Peterson Institute for International Economics, an international forum for policymakers, financial professionals, and academics focused on global economic and financial
policy issues.


4:00 PM - 4:30 PM

Wednesday August 24, 2022

The Health Tech Outlook: M&A, Private Capital, and the Policy Landscape (Software is Eating the World: Healthcare Services Edition)

  • Trends and themes behind the recent surge in HCIT M&A activity, particularly via private equity
  • Key drivers of valuation for HCIT firms in the private and public markets
  • Convergence of health tech and MSOs / tech-enabled services firms
  • Impact of recent policy shifts and upcoming changes in the landscape
View Full Agenda